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Summary Using in vitro techniques, bone marrow (BM) function has been studied in 25 patients in complete
remission and at least one year after the completion of MVPP chemotherapy for Hodgkin's disease. The
numbers of granulocyte/macrophage (GM-CFC) and fibroblastoid (CFU-F) progenitors were significantly
lower than controls and there was no evidence of any improvement with time (median months off treatment
was 30 for GM-CFC and 34 for CFU-F). In long-term BM culture production of haemopoietic cells were
strikingly lower in the post-MVPP group and the development of adherent stromal cell populations was also
significantly less. In addition, the yield of GM-CFC in adherent layers after four weeks of culture was
significantly lower than in controls. We conclude that following MVPP chemotherapy and in apparently
disease free and haematologically normal individuals there is evidence of impaired BM function up to nine
years after the completion of treatment. These abnormalities may be relevant to the known increased risk of
acute non-lymphocytic leukaemias in this group of patients and are likely to render the BM less able to
withstand subsequent insults such as further chemotherapy or infection. The eventual development of BM
failure is also a possibility and long-term follow-up of these patients is essential.
The introduction of multi-agent cytotoxic chemotherapy
given intensively on an intermittent basis by De Vita et al.
(1980) in the early 1960s has revolutionised the treatment of
generalised Hodgkin's disease (HD). The long-term survival
of patients treated with MOPP or MVPP for stages IIIB and
IV Hodgkin's disease is approximately 60% (Nicholson et
al., 1970; Sutcliffe et al., 1978; Wagstaff et al., 1988); a figure
which compares with less than 5% during the period in
which single agent therapy was in vogue. Such welcome
improvements in treatment have resulted in an increasing
number of patients surviving long enough for any chronic
effects of cytotoxic therapy on normal tissues to become
manifest and myocardial (Bonadonna et al., 1969), pulmon-
ary (Sostmann et al., 1977), and gonadal damage (Shalet,
1980) following chemotherapy are all well described.
Acute myelosuppression is the most common cause of
treatment delay or dose reduction in cancer chemotherapy
and the long term effects of these treatments on bone marrow
(BM) function are therefore of interest. Using a mouse
model, Morley and Blake (1974) described three distinct
haematological phases following treatment with busulphan.
The first phase, acute myelosuppression, resulted in a small
mortality due to infection. The second and longest phase was
one of apparent haematological normality characterised by
normal BM cellularity and peripheral blood counts. In the
third phase, mortality was high due to infection or haemorr-
hage secondary to BM aplasia or, in only a few animals,
acute leukaemia. Eighty per cent of the treated mice had died
by the 240th day; a period of roughly one-third of a normal
life span in mice. Such universal and profound effects have
fortunately not been observed in patients following conven-
tional chemotherapy but acute non-lymphocytic leukaemias
(ANLL), sometimes preceded by myelodysplastic states, do
occur. In a study of 473 patients treated with MOPP and/or
radiotherapy for HD at the NCI (Tester et al., 1974), the
estimated risk of ANLL at ten years was 2% following
chemotherapy alone, 6% following chemotherapy and radio-
therapy as primary treatment and 9% after combined modal-
ity therapy used in the salvage setting. Other groups (Boivin
et al., 1981; Coleman et al., 1982; Glickman et al., 1982;
Pedersen-Bjegaard et al., 1982) have published similar results
although higher risks (6%) of secondary ANLL have also
been reported following chemotherapy alone (Coltman et al.,
1982). In spite of these clear suggestions that cytotoxic drugs
may have important long-term effects on the bone marrow
only one study of BM function after chemotherapy for HD
involving five patients has been published (Bull et al., 1975).
In this paper we present the results of an in vitro study of
BM function in a cohort of apparently disease free and
haematologically normal patients at least one year and up to
nine years after the completion of MVPP chemotherapy for
HD.
Materials and methods
Subjects studied
Chemotherapy treated patients A total of 25 patients gave
informed consent to aspiration of BM for research purposes.
All the patients studied fulfilled the following eligibility
criteria: prior treatment with a minimum of five cycles of
MVPP chemotherapy for histologically confirmed HD
(MVPP consists of mustine 10mg and vinblastine 10mg
both i.v. on days 1 and 8 with procarbazine 150 mg and
prednisolone 50 mg both orally on days 1-14 of a 42-day
cycle); no evidence of BM involvement at presentation (nor-
mal trephine biopsy); a minimum of one year between the
completion of chemotherapy and the date of BM sampling; a
normal peripheral blood count at the time of BM sampling
with no clinical, radiological or biochemical evidence of per-
sistent or recurrent disease.
In addition to chemotherapy some patients had received
radiotherapy to areas of initial bulk disease, but BM samples
were always taken from a site distant to any previous radia-
tion field.
Details of age, stage of disease at presentation, histology,
amount and timing of treatment and remission status of all
the patients studied were retrieved from the case notes.
Untreated controls BM samples from 20 untreated controls
were obtained from three sources: 11 patients with newly
diagnosed HD without evidence of BM involvement (follow-
ing examination of a trephine biopsy) and prior to any form
of treatment; six healthy individuals acting as allogenic BM
donors for related patients undergoing BM transplantation
for acute leukaemia; surgically excised ribs from three
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patients undergoing operative procedures for non-malignant
conditions.
Preparation ofBM samples
Fresh aspirated samples of BM were mixed with 10ml of
medium (Iscove's Modified Dulbecco's Medium, IMDM,
plus 600 units of mucous heparin) in a sterile container. BM
cells were removed from specimens of rib by flushing the
exposed cortical bone with IMDM. Suspensions of BM were
washed by alternate centrifugation and resuspension of the
cell pellet in fresh IMDM and the red cells removed using
1% methyl cellulose. After appropriate dilution, nucleated
cells were counted using a Neubauer haemocytometer and
the cell count per ml of suspension was calculated. If neces-
sary, cell suspensions were adjusted to a concentration of
2x 106ml-' by adding IMDM.
Clonogenic assays
Granulocyte macrophage colony forming cells (GM-CFC)
To I ml each of fetal calf serum (FCS, Flow Laboratories,
UK) and conditioned medium [derived from the human
bladder carcinoma line, 5637, as the source of colony stimu-
lating factors (Myers et al., 1984)], were added between
5 x 104 and 5 x 105 nucleated BM cells and sufficient IMDM
to make a final volume of 4.5 ml in a sterile plastic universal
container. Then, 0.5 ml of molten agar (0.33%) was mixed
thoroughly with the cell suspension and 1 ml aliquots of this
mixture were pipetted into each of three small culture dishes
(Falcon, New Jersey, USA). Triplicate culture plates were
cooled rapidly at 4°C for about 10 min and then incubated at
37°C in a humidified atmosphere containing 5% carbon di-
oxide in air. After 11 days, GM colonies (aggregates of 50
cells or more) were counted.
Colony forming units fibroblastoid (CFU-F) This quantita-
tive assay which detects a normal component of the marrow
stroma (Friedenstein et al., 1974), was performed by adding
1.5 x 106 nucleated BM cells to IMDM plus 15% pretested
FCS to make a final volume of 15 ml in a 50 ml capacity
tissue culture flask (Falcon, New Jersey, USA). The mixture
was divided equally between three flasks which, after gassing
with 5% CO2 in air were stoppered and incubated at 37°C.
After 11 days the supernatant was discarded, the adherent
cells washed with phosphate buffered saline and then fixed
with methanol for two minutes. After staining with 1%
crystal violet, colonies (aggregates of 50 cells or more) were
counted.
Long-term bone marrow culture Cultures were established
with 1.5 x10' nucleated BM cells in 10 ml of IMDM plus
10% pretested FCS, 10% pretested horse serum and
5 x l0-' M hydrocortisone in 50 ml capacity culture flask
(Coutinho et al., 1986). After gassing with 5% CO2 in air, the
flask was stoppered and incubated 33°C in the dark. Flasks
were fed weekly by removing half the supernatant and
replacing with fresh medium. A nucleated cell count and
GM-CFC assay were performed on the culture fluid removed
and from these data the cell count and GM-CFC per total
supernatant were calculated.
Adherent layer confluence was assessed by examining
multiple fields of the flask base under low power and
estimated the total area of plastic covered by stromal cells
expressed as a fraction of the total flask base area.
Cell counts and GM-CFC assays were also performed on
adherent layer cells following trypsination (Coloumbel et al.,
1983). The supernatant of four week old cultures was remov-
ed and the adherent layer gently washed with IMDM to
remove any remaining non-adherent cells. Two to three ml of
a 0.25% solution of trypsin were added to the flask and
incubated at 37°C for no longer than five minutes until the
adherent layer fragmented. Trypsin digestion was halted by
adding IMDM with 20% FCS and a single cell suspension
obtained by gently pipetting up and down. Two cell washes
were performed before use.
Results
Clinical characteristics ofpatients studied
Of the 25 patients in this study, 10 were male and 15 were
female. Median age at presentation was 28 years (range
18-60). Thirteen of 25 had nodular sclerosing histology,
eight were mixed cellularity, three were lymphocyte predomi-
nant and one was lymphocyte depleted. Nineteen of 25
patients (76%) had stage III or IV disease, five (20%) were
stage II and just one patient was stage I. Rather less than
half the group (11 of 25) had been subjected to staging
laparotomy; the remainder had been clinically staged. None
of the patients in this study had BM involvement. Patients
received a median of seven cycles of MVPP (range five to
nine) and 15 of 25 also had radiotherapy. These data are
summarised in Table I. All the patients achieved a complete
remission and 21 of 25 remain alive and disease free. Four
patients have died, one from acute myeloid leukaemia (M6
subtype according to the FAB system (Bennett et al., 1976))
38 months after the completion of treatment, one from septi-
caemia following the sixth cycle of salvage chemotherapy for
relapsed HD at 126 months, one from progressive HD at 77
months and one from carcinoma of the bronchus at 66
months.
In vitro studies ofBMfunction
Clonogenic assays on fresh BM A total of 35 samples (19
controls, 16 post MVPP) were assayed for GM-CFC (Figure
la). Median time from end of chemotherapy was 30 months
(range 13-77). The median score for GM-CFC per 105 nucle-
ated BM cells was 69 (range 7-140) for untreated controls
and 17 (range 2-53) for patients following MVPP. This
difference is highly significant (P<0.001, Mann-Whitney U
test).
A total of 34 BM samples (13 controls, 21 post MVPP)
were assayed for CFU-F (Figure lb). Median time from end
of treatment was 34 months (range 10-109). The median
Table I Clinical characteristics of patients studied
Total
Male
Female
Median age at diag-
nosis, years (range)
25
10
15
28 (18-60)
Histology
NS 13 (52%)
MC 8 (32%)
LP 3 (12%)
LD 1 (4%)
Stage
IA I (IPS) I 1 (4%)
IIA I II 5 (20%)
B 4 (IPS)
IIIA 37 (4PS) III 10 (40%) B 3 (3PS)
IVA 3 (2PS) IV 9 (36%) (No bone marrow
B 6 (IPS) involvement)
Median no. cycle of
MVPP (range) 7 (5-9)
Radiotherapy
Total 15 (60%)
Mediastinum 6
Mantle 4
Chest 3
Neck 2
Histology: NS, nodular sclerosing; MC, mixed cellularity; LP,
lymphocyte predominant; LD, lympocyte depleted. Stage: PS,
pathological stage, refers to number of patients undergoing staging
laparotomy.BONE MARROW FUNCTION AFTER MVPP 129
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Figure 2 Scattergram of GM-CFC score (0) per 105 BM cells
and CFU-F score (0) per 5 x 105 BM cells by time in months
between the end of chemotherapy and assay. There is no correla-
tion between either score and time (Spearman's p is -0.03 for
GM-CFC and 0.06 for CFU-F).
v
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(n = 13) (n = 21)
Figure 1 a, GM-CFC colonies per l05 BM cells for 19 normal
controls and 16 patients following MVPP. b, CFU-F colonies per
l01 BM cells for 13 normal controls and 21 patients following
MVPP. For both a and b, assays were performed at least one
year after the completion of chemotherapy and in all cases the
peripheral blood count was normal. The horizontal bar lies at the
median.
colony count per 5 x 105 cells was 46 (range 25-70) for
controls, and 24 (range 3-46) for the treated group. This
difference is also highly significant (P<0.001,
Mann-Whitney U test). No correlation was observed
between the GM-CFC or CFU-F score and the time elapsed
since completion of chemotherapy (Spearman's p =-0.03
for GM-CFC and 0.06 for CFU-F, Figure 2).
Long-term BM cultures; total cells and GM-CFC The med-
ian values of the total nucleated cells and GM-CFC in the
supernatant over time for control and post chemotherapy
BM are shown in Figure 3a and b. The total number of
supernatant cells in both populations declined in a very
similar way for the first three weeks of culture; thereafter cell
numbers in control cultures plateaued but continued to fall in
the test cultures to a level approximately one sixth of this.
For GM-CFCs significant differences between the two groups
were evident from the beginning of culture; these were max-
imal between weeks 4 and 6 when up to a 10-fold difference
in median values was observed. From week 7 there was
evidence of some recovery in numbers of GM-CFC in the
chemotherapy treated group but even at best (week 8)
median values were still about five times higher in the control
cultures. Results obtained from trypsinised adherent layers at
4 weeks are summarised in Figures 4a and b. A significant
difference in numbers of GM-CFC (P = 0.01) but not of
total cells (P = 0.76) was observed between the two groups.
These results are consistent with the supernatant data where
clear differences in the numbers of total nucleated cells were
only becoming apparent at week 4 in contrast to the numbers
of GM-CFC which were exhibiting maximal differences
between the two groups by this time (Figures 3a and b).
Long-term BM culture; adherent layer development For both
control and chemotherapy treated BM in long-term culture,
further extension of non-confluent adherent layers was not
observed beyond six weeks, with many control cultures
achieving confluence by three or four weeks. The degree of
flask base coverage at six weeks was therefore regarded as a
measure of maximal adherent cell area achievable by a given
culture.
In 18 of 20 control samples cultured for six weeks, the
adherent layer was either confluent or near confluent (>80%
of flask base covered) and in the remaining two cases, 60 and
70% respectively of the flask base area was covered by
adherent cells. In contrast, adherent layers formed by BM
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Figure 4 Plots of total nucleated cells (a) and GM-CFC (b)
obtained from adherent layer trypsinised at four weeks of long-
term BM culture.
10 I
Weeks
Figure 3 Median values and range for number of total nucleated
cells (a) and GM-CFC (b) in the supernatant of 19 control and
16 post-chemotherapy BM samples in long-term culture.
from chemotherapy treated patients achieved 100% con-
fluence by week 6 in only two of 16 cultures. Cultures from
three patients achieved 60 or 70% flask base coverage, but in
eleven cases only 50% or less of the flask base area was
colonised by adherent cells. These data are represented in
Figure 5.
Discussion
In this study, significant differences were observed between
patients previously treated for HD with MVPP chemo-
therapy and untreated controls across a range of in vitro tests
of BM function. At the time of study all the patients were
clinically well, had no evidence of disease and were haema-
tologically normal by routine laboratory parameters. It is of
interest however, that of the four patients who have since
died, one succumbed with acute myeloid leukaemia and
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Figure 5 Histogram comparing development of stromal cell
adherent layer at six weeks of long term BM culture in 20
controls and 16 patients following MVPP (P<0.002).
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another with neutropenic sepsis following further
chemotherapy for relapsed HD.
The number of both GM-CFC and CFC-F in samples of
bone marrow were significantly lower in patients following
MVPP than in controls. Interestingly, there was no correla-
tion between either score and the time elapsed (up to nine
years) after completion of chemotherapy, indicating that
recovery with time may not occur. This is in agreement with
data derived from murine models where, after a variety of
chemotherapeutic regimens, no further recovery is observed
during the remaining life span of the mouse once the acute
recovery phase is over (reviewed by Testa et al., 1985). In
long-term culture, BM from controls performed markedly
better than that from chemotherapy-treated patients both in
terms of total nucleated cells and of GM-CFC measured in
the supernatant over time. A significant difference between
the groups was also seen in the number of GM-CFC from
trypsinised adherent layer at four weeks, confirming that the
differences observed in numbers of supernatant GM-CFC
were not due to differential rates of release of these cells from
the adherent layer, but rather to a real shortfall in produc-
tion.
Adherent layer formation after six weeks of LTC was
strikingly subnormal in the post-chemotherapy population.
Extension of the adherent layer is achieved in part by fibro-
blastoid cells, a component of the stromal cell compartment
and detectable by the CFU-F assay. The sigificantly lower
number of CFU-F found in BM from chemotherapy-treated
patients therefore accords well with the reduced adherent
layer confluence of these samples in LTC and both sets of
data raise the possibility of a stromal cell defect, in addition
to the probable stem cell damage which has long been recog-
nised. This is relevant because haematopoiesis both in vivo
and in long-term BM culture occurs within a complex micro-
environment composed of various stromal cell types which
probably exert local control on cell growth and different-
iation (Dexter et al., 1984). Damage to this compartment
may therefore have important implications for the regulation
of haemopoiesis.
Acute myelotoxicity is an invariable accompaniment of
cytotoxic therapy sometimes leading to infective or haemorr-
hagic complications and delays or curtailment of subsequent
treatment. Once chemotherapy is completed, however, peri-
pheral blood counts usually recover rapidly and there is a
return to apparent haematological normality. Despite this,
patients achieving prolonged survival following treatment
have a far higher incidence of actue non-lymphocytic leuk-
aemia than the general population, a fact which is generally
thought to be related to their previous exposure to cytotoxic
agents. If this is the case, sub-clinical evidence of disturbed
BM function some time after the completion of chemo-
therapy might reasonably be expected. In the mouse, Morley
et al. (1975) identified chronic BM damage affecting both the
stem and stromal cell compartments during the period of
'haematological latency' following treatment with busulphan.
In man, however, only a few studies of bone marrow func-
tion some time after the completion of chemotherapy for
lymphoproliferative disease are reported in the literature.
Bull et al., reporting in 1975, found normal levels of GM-
CFC 1.5-6 years after treatment with MOPP for HD in five
patients and concluded that there was no evidence of per-
manent damage to these granulocyte precursors following
intensive chemotherapy. It is of note that, only one of the
treated patients in our study had a level of GM-CFC in BM
that fell outside the normal range but nevertheless a highly
significant difference was observed when a comparison was
made between the two populations. Hartmann et al. (1979)
found a reduction in the number of GM-CFC in 18 children
treated for non-Hodgkin's lymphoma between 1 and 19
months following chemotherapy but in a study of 30 children
treated for acute lymphoblastic leukaemia (ALL) no such
reduction was identified between 6 months and 3.5 years
after treatment (Inoue et al., 1980). Haworth et al. (1982)
also found no evidence ofchronic BM damage as assessed by
GM-CFC levels in 37 patients who had received standard
amounts of chemotherapy for ALL but in a further six
patients who received additional cytotoxic treatment for tes-
ticular or haematological relapse a significant reduction in
GM-CFC was observed. In a later study of 20 children in
unmaintained remission three months to three years after
completion of more intensive chemotherapy for ALL, a
significantly lower number of GM-CFC was found in the
BM and in long-term culture (Bhavnani et al., 1988). Fur-
thermore, patients who had received additional treatment for
relapse had a tendency to lower levels of GM-CFC than
those receiving standard treatment and there was no evidence
of any improvement in levels of GM-CFC with time.
Our study is the first to examine the long-term effects of
MVPP chemotherapy for Hodgkin's disease on BM function
in a large sample of patients and using several in vitro
techniques. We have found that in apparently disease free
and haematologically normal individuals there is evidence of
BM damage, which may not be reversible, up to several years
after the completion of treatment. These abnormalities coin-
cide with normal numbers of cells in the peripheral blood,
presumably achieved through compensatory mechanisms
which come into play during stress haematopoiesis, and
which may also achieve normal production of mature cells
from a damaged BM during steady state (Testa et al., 1988).
However, these defects are likely to result in an impaired
response to periods of increased demand on the BM, such as
infection or further chemotherapy, and may be relevant to
the evolution of secondary leukaemias in this group of
patients. Moreover, the effects ofageing on these populations
are not yet known. In previously untreated mice some
workers have found evidence of reduced haemopoietic func-
tion in old compared to young animals (Mauch et al., 1982)
but this has not been confirmed by other groups (Schofield,
1986). However, following a severe insult to the BM such as
that resulting from cytotoxic therapy, any ageing process
might become more readily apparent and result in clinically
important syndromes related to BM hypoplasia or aplasia
similar to the effects seen in the busulphan-treated mice of
Morley and Blake (1974).
We conclude that following curative chemotherapy for
HD, bone marrow function may be chronically impaired, a
possibility not excluded by a normal peripheral blood count.
Whether the in vitro evidence of chronic BM damage de-
scribed here will, after many years, be translated into
clinically relevant cytopenias of the peripheral blood is un-
known and we consider that the long-term surveillance of
these patients is essential.
We are indebted to our patients without whose generous co-
operation none of these studies would have been possible. We also
wish to thank Ric Swindell, Department of Medical Statistics, for his
expert assistance and Marjorie Evans for her careful preparation of
the manuscript. J.A.R. was in receipt of a Leukaemia Research Fund
fellowship during the course of this study. N.G.T. is supported by
the Cancer Research Campaign, UK.
References
BENNETT, J.M., CATOVSKY, D., DANIEL, M. & 4 others (1976).
Proposals for the classification of the acute leukaemias. Br. J.
Haematol., 33, 451.
BHAVNANI, M., MORRIS JONES, P.H. & TESTA, N.G. (1988). Child-
ren in long term remission after treatment for acute lymphoblas-
tic leukaemia show persisting haemopoietic injury in clonal and
long term cultures. Br. J. Haematol., 71, 37.132 J.A. RADFORD et al.
BOIVIN, J.F. & HUTCHINSON, G.B. (1981). Leukaemia and other
cancers after radiotherapy and chemotherapy for Hodgkin's
disease. J. Natl Cancer Inst., 67, 751.
BONADONNA, G. & MONFARDINI, S. (1969). Cardiac toxicity due to
daunorubicin. Lancet, i, 837.
BULL, J.M. DE VITA, V.T. & CARBONE, P.P. (1975). In vitro
granulocyte production in patients with Hodgkin's disease and
lymphocytic, histiocytic and mixed lymphomas. Blood, 45, 833.
COLEMAN, C.N., KAPLAN, H.S., COX, R., VARGHESE, A., BUTTER-
FIELD, P. & ROSENBERG, S.A. (1982). Leukaemias, non Hodg-
kin's lymphomas and solid tumours in patients treated for Hodg-
kin's disease. Cancer Surv., 1, 733.
COLOUMBEL, L., EAVES, A.C., & EAVES, C.J. (1983). Enzymatic
treatment of long term human marrow cultures reveals the
preferential location of primitive haemopoietic progenitors in the
adherent layer. Blood, 62, 291.
COLTMAN, C.A. & DIXON, A.O. (1982). Second malignancies comp-
licating Hodgkin's disease: a south west oncology group 10 year
follow up. Cancer Treat. Rep., 66, 1023.
COUTINHO, L.H., TESTA, N.G. & DEXTER, T.M. (1986). The
myelosuppressive effects of recombinant interferon gamma in
short term and long term marrow cultures. Br. J. Haematol., 63,
517.
DE VITA, V.T., SIMON, R.M., HUBBARD, S.M. & 6 others (1980).
Curability of advanced Hodgkin's disease with chemotherapy.
Ann. Intern. Med., 92, 587.
DEXTER, T.M., SIMMONS, P., PURNELL, R.A., SPOONCER, E. &
SCHOFIELD, R. (1984). The regulation of haemopoietic cell
development by the stromal cell environment and diffusible
regulatory molecules. In Aplastic Anaemia: Stem Cell Biology and
Advances in Treatment, Young, N.S., Levine, A.S. & Humphries,
R.K. (eds) p. 13. Alan R Liss: New York.
FRIEDENSTEIN, A.J., DERIGLASOVA, U.F., KULAGINA, N.N. & 4
others (1974). Precursors for fibroblasts in different populations
of haemopoietic cells as detected by the in vitro colony assay
method. Exp. Haematol., 2, 83.
GLICKMAN, A.S., PAJAK, T.F. & GOTTLIEB, A. (1982). Second malig-
nant neoplasms in patients successfully treated for Hodgkin's
disease: a cancer and leukaemia group B study. Cancer Treat.
Rep., 66, 1035.
HARTMANN, D., PARMENTIER, C., LAMERLE, J., GOUT, M. &
SCHWEISGUTE, 0. (1979). Sequential study of the bone marrow
granulocyte progenitor cells (CFC) in children treated by
chemotherapy for non-Hodgkin malignant lymphoma. Nouv. Rev.
Fr. Haematol., 21, 239.
HAWORTH, C., MORRIS-JONES, P.H. & TESTA, N.G. (1982). Long
term bone marrow damage in children treated for ALL; evidence
from in vitro colony assays (GM-CFC and CFC-F). Br. J.
Cancer, 46, 918.
INOUE, S., RAVINDRANATH, Y., LUSHER, J.M. & ITO, T. (1980).
Haematological parameters and marrow in vitro colony forming
cells in acute lymphoblastic leukaemia, after cessation of treat-
ment. Nippon Ketsueki Gakkai Zasshi, 43, 61.
MAUCH, P., BOTNICK, L.E., HANNON, E.C., OBBAGY, J. & HELMAN,
S. (1982). Decline in bone marrow proliferative capacity as a
function of age. Blood, 60, 245.
MORLEY, A. & BLAKE, J. (1974). An animal model of chronic
aplastic marrow failure. 1. Late marrow failure after busulphan.
Blood, 44, 49.
MORLEY, A., TRAINOR, K. & BLAKE, J. (1975). A primary stem cell
lesion in chronic hypoplastic marrow failure. Blood, 45, 681.
MYERS, C.D., KATZ, F.E., JOSHI, E. & MILLAR, J.L. (1984). A cell
line secreting stimulating factors for CFU-GEMM. Blood, 64,
152.
NICHOLSON, W.M., BEARD, M.E.J., CROWTHER, D. & 5 others
(1970). Combination chemotherapy in generalised Hodgkin's
disease. Br. Med. J., iii, 7.
PEDERSEN-BJEGAARD, J. & LARSEN, S.O. (1982). Incidence of acute
non lymphocytic leukaemia, preleukaemia and acute myelo-
proliferative syndrome up to 10 years after treatment for Hodg-
kin's disease. N. Engl. J. Med., 307, 965.
SCHOFIELD, R., DEXTER, T.M., LORD, B.I. & TESTA, N.G. (1986).
Comparison of haemopoiesis in young and old mice. Mech.
Ageing Dev., 34, 1.
SHALET, S.M. (1980). Effects of cancer chemotherapy on gonadal
function of patients. Cancer Treat. Rev., 7, 141.
SOSTMANN, H.D., MATTAY, R.A. & PUTMAN, C.E. (1977). Cytotoxic
drug induced lung disease. Am. J. Med., 62, 608.
SUTCLIFFE, S.B., WRIGLEY, P.F.M., PETO, J. & 5 others (1978).
MVPP chemotherapy regimen for advanced Hodgkin's disease.
Br. Med. J., i, 679.
TESTA, N.G., BHAVNANI, M., WILL, A. & MORRIS-JONES, P.H.
(1988). Long term bone marrow damage after treatment for acute
lymphoblastic leukaemia. In Hematopoiesis: Long Term Effects of
Chemotherapy and Radiation, Testa, N.G. & Gale, R.P. (eds)
p. 279. Dekker: New York.
TESTA, N.G., HENDRY, J.H. & MOLINUEX, G. (1985). Long term
bone marrow damage in experimental systems and in patients
after radiation or chemotherapy. Anticancer Res., 5, 101.
TESTER, W.S., KINSELLA, T.G., WAHER, B. & 4 others (1984). Second
malignant neoplasms complicating Hodgkin's disease: the
National Cancer Institute experience. J. Clin. Oncol., 2, 762.
WAGSTAFF, J., GREGORY, W.M., SWINDELL, R., CROWTHER, D. &
LISTER, T.A. (1988). Prognostic factors for survival in stage IIIB
and IV Hodgkin's disease: a multivariate analysis comparing two
specialist treatment centres. Br. J. Cancer, 58, 487.